drugset
drugset / Trial / NCT07073638

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis

NCT07073638 ↗

Phase 2 Recruiting 24 enrolled Thirty Respiratory Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis

Timeline

Start
2025-10-13
Primary completion
2026-09-15
Completion
2026-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject RESP30TB Unknown 6 ml Inhaled
Background Ethambutol Small molecule 275 mg Oral
Background Isoniazid Small molecule 75 mg Oral
Background Pyrazinamide Small molecule 400 mg Oral
Background Rifampin Small molecule 150 mg Oral

Indications

pulmonary tuberculosis